 | The topic of this article may not meet Misplaced Pages's general notability guideline. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "OBI Pharma, Inc." – news · newspapers · books · scholar · JSTOR (February 2024) (Learn how and when to remove this message) |
 | This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "OBI Pharma, Inc." – news · newspapers · books · scholar · JSTOR (February 2024) (Learn how and when to remove this message) |
| Native name | 台灣浩鼎生技股份有限公司 |
|---|---|
| Company type | Public |
| Traded as | TWSE: 4174(TPEx) |
| Industry | Pharmaceuticals |
| Founded | 2002 |
| Headquarters | 19F., No.3, Yuanqu st., Nangang, Taipei, Taiwan |
| Key people | Kung-Yee Liang (Chairman) |
| Website | www.obipharma.com |
 | This section needs expansion. You can help by adding to it. (February 2020) |
OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.
In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).
History
The company was founded by Micheal N.Chang on April 29, 2002. It was formerly a subsidiary of Optimer Pharmaceuticals.
On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share.
On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.
On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.
Primary Focus
The company mainly concentrates on the development of the research and development of cancer therapies and high quality drugs.
References
- "OBI Pharma signs cancer drug deal with HK's Odeon - Taipei Times". www.taipeitimes.com. 2022-02-24. Retrieved 2024-04-19.
- "Odeon Therapeutics acquires China rights to two cancer therapy candidates from Obi Pharma in $200M deal | BioWorld". www.bioworld.com. Retrieved 2024-04-19.
- "FDA grants ODD to OBI Pharma's lead investigational drug candidate". www.biospectrumasia.com. Retrieved 2024-04-19.
- "OBI Pharma Inc. Company & People | 4174". Barron's. Retrieved 2024-02-20.
- "OBI Pharma, Inc | LinkedIn". www.linkedin.com. Retrieved 2024-02-20.